Integrating multisector molecular characterization into personalized peptide vaccine design for patients with newly diagnosed glioblastoma

CONCLUSIONS: Collectively, our findings suggest NeoVax did stimulate expansion of neoantigen-specific effector T cells and provide encouraging results to aid in the development of future neoantigen vaccine-based clinical trials in patients with GBM. Herein, we demonstrate the feasibility of incorporating multisector sampling in cancer vaccine design and provide information on the clinical applicability of clonality, distribution, and immunogenicity of the neoantigen landscape in GBM patients.PMID:38639919 | DOI:10.1158/1078-0432.CCR-23-3077

Source: Clinical Cancer Research - April 19, 2024 Category: Cancer & Oncology Authors: Tanner M Johanns Elizabeth A R Garfinkle Katherine E Miller Alexandra J Livingstone Kaleigh F Roberts Lakshmi Prakruthi Rao Venkata Joshua L Dowling Michael R Chicoine Ralph G Dacey Gregory J Zipfel Albert H Kim Elaine R Mardis Gavin P Dunn Source Type: research